Breast Cancer Drug Trastuzumab (Herceptin) Shows Unprecedented Survival In Aggressive

[News]

Data from the ToGA study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida showed that adding trastuzumab to standard chemotherapy (capecitabine [Xeloda®] or intravenous 5-FU and cisplatin) prolongs the lives of patients with this aggressive cancer on average by nearly 2.7 months to 13.8 months, a 26% increase in survival.

More... (http://www.medicalnewstoday.com/articles/152370.php)